Peptide Comparison
GHK-Cu vs BPC-157
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Depends on goal
These two get grouped together because both are described as repair compounds, and they are studied in almost entirely separate literatures. GHK-Cu has controlled cosmetic and dermatological studies behind topical use on skin endpoints. BPC-157 has rodent tissue-repair data and no published human randomized trial. The overlap most readers assume is mostly the shared word. Consult a qualified clinician before any human use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
GHK-Cu is a copper-binding matrikine tripeptide that delivers copper to receptors and shifts expression of a large set of genes governing collagen, elastin and decorin synthesis. Its controlled evidence sits in topical formulations at 0.05 to 2 percent. BPC-157 is a synthetic pentadecapeptide reported to promote angiogenesis through VEGFR2 and to stabilize the gut barrier, studied systemically in animals. The FDA compounding record lists both among substances nominated for the bulks lists and later withdrawn, and BPC-157 additionally received a favorable advisory committee recommendation on 23 July 2026 by 8 votes to 6 with 1 abstention, which is a recommendation rather than an approval.
Which one to pick
Pick GHK-Cu if
- The endpoint is skin: collagen, elastin, wound appearance or hair follicle work
- Topical application is the intended route, which is where the controlled evidence sits
- Cosmetic-grade formulation and labelling are acceptable for the purpose
Pick BPC-157 if
- The endpoint is gastrointestinal mucosal repair, where the rodent literature concentrates
- The reference question concerns tendon or ligament work, where the reports concentrate even though controlled human data is absent
- The current US compounding position matters, since BPC-157 is the one of the two under active regulatory reconsideration
Avoid both if
- There is a personal or family history of cancer, given that both carry unresolved pro-angiogenic and proliferative concerns
- Injectable use is contemplated, since neither has established systemic human safety data and injectable GHK-Cu appears by name on the FDA withdrawn-nomination list
- Pregnancy or planning pregnancy
Used together in
- GLOW / KLOW: Tissue repair, anti-inflammation, skin regeneration
Shared safety considerations
Both compounds share these reported concerns: injection site irritation. Open each peptide page for the full risk paragraph and source citations.
Common confusions
- 'GHK-Cu and BPC-157 do the same job'. No. One modulates copper-dependent gene expression in skin, the other is reported to act on VEGFR2 and the gut barrier. They appear together in the same protocols because the proposed effects do not overlap, not because they do.
- 'The cosmetic studies on GHK-Cu support injecting it'. They do not. That evidence is topical and measures skin endpoints. Injection is a different route, a different exposure and a different risk profile, and the FDA lists injectable GHK-Cu among withdrawn nominations by name.
- 'BPC-157 was banned from compounding in 2023'. Out of date. It was nominated for the bulks lists, flagged, and the nomination was withdrawn. On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee recommended it for the 503A Bulks List by 8 votes to 6 with 1 abstention. The vote binds nothing and no rule has issued, but the 2023 framing no longer describes the position.
Side-by-side
| GHK-Cu | BPC-157 | |
|---|---|---|
| Class | Matrikine copper-tripeptide | Synthetic pentadecapeptide; cytoprotective |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis | Promotes angiogenesis via VEGFR2 [1]; upregulates growth factors [1]; modulates NO and dopamine pathways [1]; stabilizes gut barrier [1] |
| Route | Topical / SC / Microneedling | SC / IM / Oral / Intranasal |
| Half-life | Varies by formulation | less than 30 min (IV and IM in rats and dogs; oral not measured) |
| Dosage (research) | Topical 0.05-2% (cosmetic standard); 1 mg SC daily (Seeds Vol 1 starting dose, range up to 3 mg/day per r/Peptides wiki); microneedling 0.1-0.5% | 250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily |
| Evidence tier | Cosmetic Clinical + Animal Studies | Anecdotal + Animal Studies |
| Research depth | 122 indexed | 174 indexed |
| Availability | Cosmetic / Research | Compounding Restricted |
| Reported risks | Injection site irritation; theoretical copper toxicity at high doses; limited systemic safety data | Limited human trials [1]; injection site irritation; theoretical pro-angiogenic/tumor concerns [1] |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHK-Cu or BPC-157?
These two get grouped together because both are described as repair compounds, and they are studied in almost entirely separate literatures. GHK-Cu has controlled cosmetic and dermatological studies behind topical use on skin endpoints. BPC-157 has rodent tissue-repair data and no published human randomized trial. The overlap most readers assume is mostly the shared word. Consult a qualified clinician before any human use.
What is the difference between GHK-Cu and BPC-157?
GHK-Cu is classed as Matrikine copper-tripeptide; BPC-157 is classed as Synthetic pentadecapeptide; cytoprotective. Reported mechanism: GHK-Cu, Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis; BPC-157, Promotes angiogenesis via VEGFR2; upregulates growth factors; modulates NO and dopamine pathways; stabilizes gut barrier. Reported half-life: GHK-Cu, Varies by formulation; BPC-157, less than 30 min (IV and IM in rats and dogs; oral not measured). Routes in published studies: GHK-Cu, Topical / SC / Microneedling; BPC-157, SC / IM / Oral / Intranasal.
Which has stronger evidence, GHK-Cu or BPC-157?
GHK-Cu has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK-Cu is graded Cosmetic Clinical + Animal Studies, with 15 cited sources on its reference page and 122 indexed studies. BPC-157 is graded Anecdotal + Animal Studies, with 9 cited sources on its reference page and 174 indexed studies.
Which is more accessible, GHK-Cu or BPC-157?
Neither GHK-Cu nor BPC-157 is an FDA-approved drug. Catalog status: GHK-Cu, Cosmetic / Research; BPC-157, Compounding Restricted. GHK-Cu's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend BPC-157 for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are GHK-Cu and BPC-157 ever combined?
Yes. GLOW / KLOW is a documented stack containing both GHK-Cu and BPC-157; the stack page gives the stated rationale.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…